Horizon Pharma Files for IPO

Horizon Pharma Inc., a Northbrook, Ill.-based drug developer focused on arthritis, pain and inflammatory diseases, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol HZNP, with Jefferies & Co. and Piper Jaffray serving as co-lead underwriters.

The company has raised around $54 million in VC funding since its 2004 founding as Nitec Pharma. Shareholders include Atlas Venture (17.4% pre-IPO stake), Essex Woodlands Health Ventures (14%), Scale Venture Partners (13.4%), NGN Biomed (9.9%), Sutter Hill Ventures (5.9%), FirstMark Capital (7.9%), Global Life Sciences Ventures (7.8%) and TVM (5.7%). www.nitecpharma.com

Related Posts

1 Comment

Leave a Reply

PEHUB Community

Join the 12501 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget